CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 2016—Medivation and NanoString Technologies have entered into a collaboration, together with Astellas Pharma, to pursue the translation of a novel gene expression signature algorithm from Medivation into a companion diagnostic assay using NanoString’s nCounter Dx Analysis System. Under the terms of the agreement, NanoString will be responsible for developing and validating the diagnostic test, and if the parties thereafter determine to proceed, NanoString would also be responsible for seeking regulatory approval for and commercializing the diagnostic test. NanoString is eligible to receive up to $22 million for technology access, near-term milestones, and development funding in addition to other potential undisclosed downstream payments.
Under the agreement, NanoString will modify its PAM50-based Prosigna Breast Cancer Assay for potential use as a companion diagnostic test for enzalutamide for triple negative breast cancer. The modified test will be based on data from a phase two trial conducted by Medivation and Astellas that evaluated enzalutamide in patients with triple negative breast cancer.
NanoString, 888-358-6266